CP
EstablishedCeruloplasmin is the first-line screening test for Wilson's disease, a genetic copper-metabolism disorder.
Ceruloplasmin carries copper in the blood, and low levels are the classic first clue for Wilson's disease, a rare condition where copper builds up to toxic levels. It's usually ordered along with a urine copper test and sometimes genetic testing to confirm the diagnosis.
Ceruloplasmin (CP) is a copper-carrying protein synthesized by the liver, best known clinically as the first-line screening test for Wilson's disease, a genetic disorder of copper metabolism causing toxic copper accumulation.
Low ceruloplasmin (typically <0.2 g/L or below 50% of the lower normal limit) supports a Wilson's disease diagnosis, particularly when combined with elevated 24-hour urinary copper excretion and, ideally, genetic confirmation of ATP7B mutations.
Current guidance (EASL, AASLD, BASL) treats ceruloplasmin as a first screening step within the broader Leipzig diagnostic scoring system, not a standalone test. A significant real-world issue: one study found testing 2,847 patients to identify a single new late-onset Wilson's diagnosis over age 40, reflecting poor guideline adherence in test ordering.
False-positive low ceruloplasmin occurs in chronic liver disease and malnutrition, since ceruloplasmin synthesis itself depends on liver function — complicating diagnosis in patients who already have liver disease from another cause, which is often exactly the population being tested.
Requires combination with urinary copper and genetic testing within a formal scoring system; not standalone diagnostic.
- Wilson's Disease: An Update on the Diagnostic Workup and Management. (2021). PMC.
- Irish Medical Journal. (2020). The Clinical Utility of a Low Serum Ceruloplasmin Measurement in the Diagnosis of Wilson Disease.